Cenk A. Aksu
Postdoctoral Research Associate
Postdoctoral Research Associate Creating Ancestrally Inclusive Single-Cell Atlas of Healthy Musculoskeletal Tissues
I completed my molecular biology and genetic BSc at Haliç University (Turkey) in 2015. Then I pursued my academic career with a Ph. D. in cellular and molecular medicine at Koç University (Turkey). Under the supervision of Prof. Tugba Bagci-Onder, I worked on “Assessing the Epigenetic Modifiers of Drug Response in Human Astrocyte and Glioblastoma Co-Cultures”, which I defended in June 2022.
During my Ph.D. I learned several skills such as FACS, fluorescently tagged cell imaging, live cell imaging, single-cell sequencing, genetic engineering, CRISPRa/i and pooled CRISPR screen analysis, and bulk & single-cell RNAseq analysis. In my last six months, I worked with Assoc. Prof. Adam Cribbs at NDORMS (University of Oxford) and discovered my interest in single-cell technologies. Especially how the cellular ‘road-map’ connect and provide such fundamental metrics to define the diverse tissues. In 2022, I joined NDORMS as a postdoctoral research associate for the CZI Ancestrally Diverse Musculoskeletal Atlas, working with Assoc. Prof. Snelling, Assoc. Prof. Cribbs and Dr. Baldwin.
Recent publications
-
Chromatin-focused genetic and chemical screens identify BRPF1 as a targetable vulnerability in Taxol-resistant triple-negative breast cancer
Preprint
Yedier-Bayram O. et al, (2024)
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival.
Journal article
Ozyerli-Goknar E. et al, (2023), Cell commun signal, 21
-
Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival
Preprint
Ozyerli-Goknar E. et al, (2022)
-
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities.
Journal article
Yedier-Bayram O. et al, (2022), Cell death dis, 13
-
Overcoming chemoresistance in triple negative breast cancer by bromodomain inhibition
Conference paper
Yedier-Bayram O. et al, (2022), European journal of cancer, 174, S69 - S69